We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

101 hedge funds and large institutions have $349M invested in KalVista Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more call options, than puts

Call options by funds: $10.8M | Put options by funds: $4.06M

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

13% more capital invested

Capital invested by funds: $310M → $349M (+$39.2M)

7% more funds holding

Funds holding: 94 → 101 (+7)

4.59% more ownership

Funds ownership: 100.82% → 105.42% (+4.6%)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
101
Holders Change
+7
Holders Change %
+7.45%
% of All Funds
1.6%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
34
Reduced
27
Closed
10
Calls
$10.8M
Puts
$4.06M
Net Calls
+$6.7M
Net Calls Change
+$6.92M

Top Buyers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
+$9.2M
2
TCM
Tang Capital Management
California
+$8.06M
3
SVCM
Saturn V Capital Management
Texas
+$4.07M
4
SCM
Suvretta Capital Management
New York
+$3.95M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.66M

Top Sellers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
-$5.02M
2
CC
Commodore Capital
New York
-$2.81M
3
OM
Opaleye Management
Massachusetts
-$2.25M
4
MB
MPM BioImpact
Massachusetts
-$1.88M
5
WP
Woodline Partners
California
-$975K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$2.61M -$198K -19,334 -7%
NFGH
27
Nan Fung Group Holdings
Hong Kong
$2.26M +$305K +29,853 +15%
SCM
28
Silverarc Capital Management
Massachusetts
$2.2M -$5.02M -491,574 -68%
Morgan Stanley
29
Morgan Stanley
New York
$2.02M +$74.6K +7,305 +4%
Goldman Sachs
30
Goldman Sachs
New York
$2.01M -$863K -84,499 -29%
Two Sigma Advisers
31
Two Sigma Advisers
New York
$1.68M +$421K +41,200 +31%
IC
32
Ikarian Capital
Texas
$1.37M +$27.5K +2,692 +2%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
33
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.35M – – –
AA
34
AlphaCentric Advisors
Puerto Rico
$1.3M – – –
SG Americas Securities
35
SG Americas Securities
New York
$1.26M +$100K +9,794 +8%
CM
36
Caption Management
Oklahoma
$1.23M +$1.31M +127,866 New
D.E. Shaw & Co
37
D.E. Shaw & Co
New York
$1.11M -$16.1K -1,580 -1%
Connor, Clark & Lunn Investment Management (CC&L)
38
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.01M -$33.8K -3,307 -3%
Two Sigma Investments
39
Two Sigma Investments
New York
$1,000K +$47.3K +4,632 +5%
GTC
40
Ghost Tree Capital
New York
$963K +$1.02M +100,000 New
Bank of New York Mellon
41
Bank of New York Mellon
New York
$812K +$15.4K +1,508 +2%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$713K -$149K -14,600 -16%
Renaissance Technologies
43
Renaissance Technologies
New York
$665K -$754K -73,828 -52%
AI
44
Atom Investors
Texas
$629K +$324K +31,727 +95%
Charles Schwab
45
Charles Schwab
California
$627K – – –
N
46
Nuveen
North Carolina
$587K -$8.49K -831 -1%
Walleye Capital
47
Walleye Capital
New York
$562K +$596K +58,378 New
Fidelity Investments
48
Fidelity Investments
Massachusetts
$554K -$136K -13,299 -19%
Marshall Wace
49
Marshall Wace
United Kingdom
$496K +$526K +51,524 New
CWM
50
CIBC World Markets
New York
$482K – – –
1
2
3 4 5

KALV Hedge Fund Activity: Q3 2023 in Review

101 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q3 2023, worth a combined $349M — up 13% from $310M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KALV positions and 10 closed out — a net gain of 7 holders — while 34 added to existing stakes and 27 trimmed.

The largest buyer was Logos Global Management, opening a new position worth an estimated $9.2M. The largest seller was Silverarc Capital Management, cutting an estimated $5.02M.

  • 101 institutional investors held KalVista Pharmaceuticals (KALV) as of Q3 2023, up from 94 in Q2 2023.
  • Funds reported $349M of KalVista Pharmaceuticals stock for Q3 2023, up 13% quarter-over-quarter.
  • 17 funds opened new KalVista Pharmaceuticals positions in Q3 2023 and 10 closed out, a net change of +7 holders.
  • The largest KalVista Pharmaceuticals buyer in Q3 2023 was Logos Global Management, an estimated $9.2M added.
  • The largest KalVista Pharmaceuticals seller in Q3 2023 was Silverarc Capital Management, an estimated $5.02M sold.

Based on aggregated 13F filings for Q3 2023.